{"id":12397,"date":"2019-02-20T15:49:03","date_gmt":"2019-02-20T14:49:03","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=12397"},"modified":"2019-02-26T15:52:52","modified_gmt":"2019-02-26T14:52:52","slug":"sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/","title":{"rendered":"Sapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers"},"content":{"rendered":"\n

Sapreme Technologies<\/strong><\/a>, a privately-held biotech company developing a technology platform to enable the cytosolic delivery of macromolecule therapeutics, has been awarded a 6.8 M\u20ac grant together with a multidisciplinary consortium including 11 other academic and industrial parties. The grant was provided by the European Union (EU) through Horizon 2020 to develop a non-viral based gene therapy using Sapreme\u2019s proprietary endosomal escape enhancers.<\/p>\n\n\n\n

Ruben Postel, CSO of Sapreme Technologies,\u00a0\u201cWe are pleased to see that the EU has recognized the great potential of the ENDOSCAPE project and the expert multi-disciplinary consortium developing a novel oligonucleotide delivery technology for treatment of cancer and haemophilia patients\u201d<\/p>\n\n\n\n

Ernst Geutjes, acting Managing Director,<\/strong>\u00a0\u201cThe fact that the EU awarded the proposal with the maximum score demonstrates the potential of Sapreme\u2019s proprietary endosomal escape enhancement technology as well as the exceptional quality of the proposal and the consortium spearheaded by Sapreme and Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin\u201d<\/p>\n\n\n\n

Source: Sapreme Technologies<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Sapreme Technologies, a privately-held biotech company developing a technology platform to enable the cytosolic delivery of macromolecule therapeutics, has been awarded a 6.8 M\u20ac grant together with a multidisciplinary consortium including 11 other academic and industrial parties. The grant was provided by the European Union (EU) through Horizon 2020 to develop a non-viral based gene […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-12397","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"\nSapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers - hollandbio\" \/>\n<meta property=\"og:description\" content=\"Sapreme Technologies, a privately-held biotech company developing a technology platform to enable the cytosolic delivery of macromolecule therapeutics, has been awarded a 6.8 M\u20ac grant together with a multidisciplinary consortium including 11 other academic and industrial parties. The grant was provided by the European Union (EU) through Horizon 2020 to develop a non-viral based gene […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-20T14:49:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-26T14:52:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"Sapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers\",\"datePublished\":\"2019-02-20T14:49:03+00:00\",\"dateModified\":\"2019-02-26T14:52:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\\\/\"},\"wordCount\":172,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\\\/\",\"name\":\"Sapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2019-02-20T14:49:03+00:00\",\"dateModified\":\"2019-02-26T14:52:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/","og_locale":"en_US","og_type":"article","og_title":"Sapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers - hollandbio","og_description":"Sapreme Technologies, a privately-held biotech company developing a technology platform to enable the cytosolic delivery of macromolecule therapeutics, has been awarded a 6.8 M\u20ac grant together with a multidisciplinary consortium including 11 other academic and industrial parties. The grant was provided by the European Union (EU) through Horizon 2020 to develop a non-viral based gene […]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/","og_site_name":"hollandbio","article_published_time":"2019-02-20T14:49:03+00:00","article_modified_time":"2019-02-26T14:52:52+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"Sapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers","datePublished":"2019-02-20T14:49:03+00:00","dateModified":"2019-02-26T14:52:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/"},"wordCount":172,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/","name":"Sapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2019-02-20T14:49:03+00:00","dateModified":"2019-02-26T14:52:52+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/sapreme-technologies-in-a-6-8-me-eu-alliance-to-develop-an-oligonucleotide-delivery-platform-based-on-its-proprietary-endosomal-escape-enhancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Sapreme Technologies in a 6.8 M\u20ac EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/12397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=12397"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/12397\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=12397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=12397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=12397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}